Health Care Up as Backlash Fears Ease — Health Care Roundup
Health-care companies rose, as health insurers and other "middle men" recouped some of their recent losses. UnitedHealth Group, which has become the center of a public debate about health-care policy ...
BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints
Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data.
24/7 Wall St12h
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Wall Street leaps and halves its losses from what had been a dismal week
U.S. stocks are rallying Friday to more than halve their losses in what had been one of their worst weeks of the year.
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
Novo Nordisk Shares Plunge After New Obesity Shot Disappoints
Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of ...
BMO lowers Novo Nordisk price target to $105, says reaction to data ‘overdone’
BMO Capital lowered the firm’s price target on Novo Nordisk (NVO) to $105 from $156 and keeps an Outperform rating on the shares after ...
Money Morning15h
Novo Nordisk Faces 20-Year Worst Stock Drop: Bear Market Price Target Revealed
In November, NVO shares crossed into a long-term bear market as they fell below their 20-month moving average - a key ...
devdiscourse16h
Novo Nordisk's Obesity Drug Trial Raises Questions Amid Market Drop
Novo Nordisk faces scrutiny after disappointing trial results for CagriSema, a next-gen obesity drug, caused a significant market valuation drop. Analysts question whether side effects limited dosage ...